meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced - colorectal cancer (mCRC)
mCRC - 1st line (L1)
1
mCRC - 2nd line (L2)
3
endometrial cancer
1
esophageal cancer (EC)
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus cometinib
Immune checkpoint association
durvalumab plus tremelimumab
versus all
vs non active control
vs BSC
vs placebo
vs VEGF(R) inhibitor
vs regorafenib
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
Evidence gap map
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
Immune checkpoint association
durvalumab plus tremelimumab
mCRC - 2nd line (L2)
3
Comparator:
vs BSC;
Risk of bias:
low;
some concerns;
high;
NA;